STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia

Cell Reports

Volumn 15, Issue 11, 2016, Pages 2357-2366

  Curran, Emily ^a   Chen, Xiufen ^a   Corrales, Leticia ^a   Kline, Douglas E ^a   Dubensky, Thomas W ^b   Duttagupta, Priyanka ^c   Kortylewski, Marcin ^c   Kline, Justin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Aduro BioTech Inc   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; BETA INTERFERON; INTERLEUKIN 6; STING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VADIMEZAN; INTERFERON; MEMBRANE PROTEIN; MPYS PROTEIN, MOUSE; TUMOR ANTIGEN; XANTHONE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; IMMUNOLOGICAL MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ACUTE MYELOID LEUKEMIA; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETIC ENGINEERING; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; INTERFERON TYPE I; LEUKEMIA, MYELOID, ACUTE; MEMBRANE PROTEINS; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; XANTHONES;

EID: 84974694609     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.05.023     Document Type: Article

References (31)

1. Anguille S., Lion E., Willemen Y., Van Tendeloo V.F., Berneman Z.N., Smits E.L. Interferon-α in acute myeloid leukemia: an old drug revisited. Leukemia 2011, 25:739-748.
2. Chen H., Sun H., You F., Sun W., Zhou X., Chen L., Yang J., Wang Y., Tang H., Guan Y., et al. Activation of STAT6 by STING is critical for antiviral innate immunity. Cell 2011, 147:436-446.
3. Corrales L., Glickman L.H., McWhirter S.M., Kanne D.B., Sivick K.E., Katibah G.E., Woo S.R., Lemmens E., Banda T., Leong J.J., et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015, 11:1018-1030.
4. Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., Li X.D., Mauceri H., Beckett M., Darga T., et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity 2014, 41:843-852.
5. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., Lee H., Arthur C.D., White J.M., Kalinke U., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 2011, 208:1989-2003.
6. Dunn G.P., Bruce A.T., Sheehan K.C., Shankaran V., Uppaluri R., Bui J.D., Diamond M.S., Koebel C.M., Arthur C., White J.M., Schreiber R.D. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 2005, 6:722-729.
7. Fu J., Kanne D.B., Leong M., Glickman L.H., McWhirter S.M., Lemmens E., Mechette K., Leong J.J., Lauer P., Liu W., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med. 2015, 7:283ra52.
8. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 2011, 208:2005-2016.
9. Gajewski T.F. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res. 2007, 13:5256-5261.
10. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
11. Hossain D.M., Dos Santos C., Zhang Q., Kozlowska A., Liu H., Gao C., Moreira D., Swiderski P., Jozwiak A., Kline J., et al. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood 2014, 123:15-25.
12. Hwang W.T., Adams S.F., Tahirovic E., Hagemann I.S., Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol. 2012, 124:192-198.
13. Ishikawa H., Barber G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008, 455:674-678.
14. Ishikawa H., Ma Z., Barber G.N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009, 461:788-792.
15. Joseph W.R., Cao Z., Mountjoy K.G., Marshall E.S., Baguley B.C., Ching L.M. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res. 1999, 59:633-638.
16. Kuo Y.H., Landrette S.F., Heilman S.A., Perrat P.N., Garrett L., Liu P.P., Le Beau M.M., Kogan S.C., Castilla L.H. Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell 2006, 9:57-68.
17. LaBelle J.L., Truitt R.L. Characterization of a murine NKT cell tumor previously described as an acute myelogenous leukemia. Leuk. Lymphoma 2002, 43:1637-1644.
18. Mahmoud S.M., Paish E.C., Powe D.G., Macmillan R.D., Grainge M.J., Lee A.H., Ellis I.O., Green A.R. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 2011, 29:1949-1955.
19. Montoya M., Schiavoni G., Mattei F., Gresser I., Belardelli F., Borrow P., Tough D.F. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002, 99:3263-3271.
20. Müller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921.
21. Ohminami H., Yasukawa M., Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000, 95:286-293.
22. Pagès F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005, 353:2654-2666.
23. Smits E.L., Anguille S., Berneman Z.N. Interferon α may be back on track to treat acute myeloid leukemia. OncoImmunology 2013, 2:e23619.
24. Spaapen R.M., Leung M.Y., Fuertes M.B., Kline J.P., Zhang L., Zheng Y., Fu Y.X., Luo X., Cohen K.S., Gajewski T.F. Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature. J. Immunol. 2014, 193:4254-4260.
25. Spranger S., Spaapen R.M., Zha Y., Williams J., Meng Y., Ha T.T., Gajewski T.F. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 2013, 5:200ra116.
26. Sun L., Wu J., Du F., Chen X., Chen Z.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339:786-791.
27. Woo S.R., Fuertes M.B., Corrales L., Spranger S., Furdyna M.J., Leung M.Y., Duggan R., Wang Y., Barber G.N., Fitzgerald K.A., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41:830-842.
28. Wu J., Sun L., Chen X., Du F., Shi H., Chen C., Chen Z.J. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 2013, 339:826-830.
29. Zhang L., Gajewski T.F., Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009, 114:1545-1552.
30. Zhang L., Chen X., Liu X., Kline D.E., Teague R.M., Gajewski T.F., Kline J. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J. Clin. Invest. 2013, 123:1999-2010.
31. Zhao L., Ching L.M., Kestell P., Baguley B.C. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br. J. Cancer 2002, 87:465-470.